About Us
Board of Directors
Sang Hoon Lee, Ph.D.
Board Member
Sang Hoon Lee is founder of ABL Bio in 2016 with the vision to build a company that offers patients a better life based on innovative science. He has years of experience from global biopharmaceutical companies, including Chiron (Novartis), AstraZeneca, Genentech and Exelixis, where he gained cross functional knowledge in drug discovery, preclinical and clinical development of therapeutic antibodies. Dr. Lee received his Ph.D. in Molecular, Cellular and Developmental Biology at The Ohio State University and obtained his postdoctoral fellowship at the Harvard Medical School, UCSF and Stanford Medical School. He earned his M.S. in Developmental Biology and B.S. in Biology Education from Seoul National University.
Jerry Lee
Board Member
Jerry Lee is a founding member of ABL Bio, where he is responsible for all managerial and financial functions of the company, including financial strategy, capital investment, accounting, investing and public relations and risk-managing. He also oversees all global and domestic partnership activities. Jerry holds an M.B.A. and M.H.S.A. from the University of Michigan and received his B.A. in Business Administration from Korea University.
Mayank Gandhi, M.D.
CEO, Board Member
Mayank Gandhi is a physician and brings over 20 years of biopharma industry experience, with operating roles across small biotech companies and large pharma. Before co-founding NEOK, Mayank was Chief Business Officer of eFFECTOR Therapeutics, a clinical-stage public biotech developing novel cancer drugs. Before that, he was at Genentech/Roche where he held numerous oncology-focused operational and leadership roles spanning business development, medical affairs and commercial. Mayank has also been a biopharma investor and equity analyst with a deep understanding of the capital markets. Mayank earned his medical degree from University of Mumbai, India and MBA from Case Western Reserve University.
About Our Name
NEOK stands for a New Era Of Knowledge — a philosophy that drives everything we do. Our platform harnesses data, biology, and chemistry to deliver more precise, safer, and effective ADCs for patients with cancer. Our mission is simple yet bold: to turn deep knowledge into real therapeutic breakthroughs.